ScreenerHero

EWTX Edgewise Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · edgewisetx.com
39.57USD-1.12%Mkt Cap: 4.30B $P/E: —

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small mole…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.30B USD
Enterprise Value3.89B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-167.79M USD
Revenue/Share—
Last Price39.57 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees127
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.04
PEG—
EV/EBITDA-17.94
EV/Revenue—
P/S—
P/B9.63
EPS (TTM)-1.86
EPS (Forward)-1.82
52W Range
14.2574% of range48.40
52W High48.40 USD
52W Low14.25 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.13%
ROA-30.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-143.82M USD
CapEx (TTM)256.00K USD
FCF Margin—
FCF Yield-2.15%
Net Debt-457.12M USD
Net Debt/EBITDA2.11
Balance Sheet
Debt/Equity0.01
Current Ratio16.24
Quick Ratio15.86
Book Value/Sh4.16 USD
Cash/Share4.24 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)52.62 USD
Upside (mean)+33.0%
Target Range36.00 USD – 66.00 USD
36.00+33.0% to mean66.00
# Analysts13
Ownership
Shares Out.108.60M
Float74.27M
Insiders0.49%
Institutions111.69%
Short Interest
Short Ratio8.0d
Short % Float12.38%
Short % Out.8.79%
Shares Short9.54M
Short (prev mo.)9.68M
Technical
SMA 5042.87 (-7.7%)
SMA 20034.89 (+13.4%)
Beta0.35
S&P 52W Chg16.45%
Avg Vol (30d)1.31M
Avg Vol (10d)1.95M
Technical Indicators
RSI (14)41.1
MACD-0.7962
MACD Signal-0.5289
MACD Hist.-0.2673
BB Upper46.22 USD
BB Middle42.01 USD
BB Lower37.79 USD
BB Width20.07%
ATR (14)2.090 USD
Vol Ratio (20d)0.83x